Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression

Theranostics

Volumn 6, Issue 4, 2016, Pages 533-544

  Liu, Rong ^a   Shi, Peiguo ^a   Nie, Zhi ^b   Liang, Huichun ^a   Zhou, Zhongmei ^a   Chen, Wenlin ^b   Chen, Haijun ^c   Dong, Chao ^b   Yang, Runxiang ^b   Liu, Suling ^d   Chen, Ceshi ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c FUZHOU UNIVERSITY   (China)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cancer Stem Cell; KLF5; Mifepristone; miR 153; Triple negative Breast Cancer

Indexed keywords

KRUPPEL LIKE FACTOR 5; MICRORNA; MICRORNA 153; MIFEPRISTONE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KLF5 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MIRN153 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STEM CELL; CELL POPULATION; CELL PROLIFERATION ASSAY; CELL VIABILITY ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; HCC1937 CELL LINE; HUMAN; HUMAN CELL; MCF10A CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; STEM CELL; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HETEROGRAFTS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE, INBRED NOD; MICE, SCID; MICRORNAS; MIFEPRISTONE; STEM CELLS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84984788824     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.14315     Document Type: Article

References (55)

1. Desmedt C, Ruiz-Garcia E, Andre F. Gene expression predictors in breast cancer: current status, limitations and perspectives. Eur J Cancer. 2008; 44: 2714-20.
2. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011; 22: 1736-47.
3. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13: 4429-34.
4. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007; 109: 25-32.
5. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation. 2011; 121: 2750-67.
6. Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol. 2012; 30: 1879-87.
7. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138: 645-59.
8. Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nature reviews Cancer. 2012; 12: 767-75.
9. pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. J Biol Chem. 2009; 284: 16791-8.
10. Zheng HQ, Zhou Z, Huang J, et al. Kruppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1. Oncogene. 2009; 28: 3702-13.
11. Jiang J, Chan YS, Loh YH, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nature cell biology. 2008; 10: 353-60.
12. Parisi S, Passaro F, Aloia L, et al. Klf5 is involved in self-renewal of mouse embryonic stem cells. J Cell Sci. 2008; 121: 2629-34.
13. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nature genetics. 2008; 40: 499-507.
14. Liu R, Zhou Z, Zhao D, et al. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation. Mol Endocrinol. 2011; 25: 1137-44.
15. Tong D, Czerwenka K, Heinze G, et al. Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2006; 12: 2442-8.
16. Takagi K, Miki Y, Onodera Y, et al. Kruppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocrine-related cancer. 2012; 19: 741-50.
17. Zhao D, Zhi X, Zhou Z, et al. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis. 2012; 33: 59-67.
18. Zhi X, Zhao D, Zhou Z, et al. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. The American journal of pathology. 2012.
19. Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception. 2010; 82: 442-52.
20. Schneider CC, Gibb RK, Taylor DD, et al. Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig. 1998; 5: 334-8.
21. Goyeneche AA, Caron RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007; 13: 3370-9.
22. Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol. 2004; 18: 70-85.
23. Fjelldal R, Moe BT, Orbo A, et al. MCF-7 cell apoptosis and cell cycle arrest: non-genomic effects of progesterone and mifepristone (RU-486). Anticancer research. 2010; 30: 4835-40.
24. Tieszen CR, Goyeneche AA, Brandhagen BN, et al. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC cancer. 2011; 11: 207.
25. Han S, Sidell N. RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. The Journal of clinical endocrinology and metabolism. 2003; 88: 713-9.
26. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama. 2002; 288: 321-33.
27. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1: 555-67.
28. Bu W, Xin L, Toneff M, et al. Lentivirus vectors for stably introducing genes into mammary epithelial cells in vivo. Journal of mammary gland biology and neoplasia. 2009; 14: 401-4.
29. Chen C, Zhou Z, Ross JS, et al. The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer. 2007; 121: 2834-41.
30. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100: 3983-8.
31. Xu J, Liao X, Wong C. Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. International journal of cancer Journal international du cancer. 2010; 126: 1029-35.
32. Liu L, Chen R, Huang S, et al. miR-153 sensitized the K562 cells to As2O3-induced apoptosis. Med Oncol. 2012; 29: 243-7.
33. Takagi K, Miki Y, Onodera Y, et al. Kruppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocrine-related cancer. 2012.
34. Yagi N, Manabe I, Tottori T, et al. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo. Cancer research. 2009; 69: 6531-8.
35. Bialkowska AB, Crisp M, Bannister T, et al. Identification of small-molecule inhibitors of the colorectal cancer oncogene Kruppel-like factor 5 expression by ultrahigh-throughput screening. Molecular cancer therapeutics. 2011; 10: 2043-51.
36. Nandan MO, Yang VW. The role of Kruppel-like factors in the reprogramming of somatic cells to induced pluripotent stem cells. Histol Histopathol. 2009; 24: 1343-55.
37. Nakaya T, Ogawa S, Manabe I, et al. KLF5 regulates the integrity and oncogenicity of intestinal stem cells. Cancer research. 2014; 74: 2882-91.
38. Zhao S, Deng Y, Liu Y, et al. MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Molecular biology reports. 2013; 40: 2789-98.
39. Xu Q, Sun Q, Zhang J, et al. Downregulation of miR-153 contributes to epithelial-mesenchymal transition and tumor metastasis in human epithelial cancer. Carcinogenesis. 2013; 34: 539-49.
40. Xu J, Liao X, Lu N, et al. Chromatin-modifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines. Int J Cancer. 2011; 129: 2527-31.
41. Mandemakers W, Abuhatzira L, Xu H, et al. Co-regulation of intragenic microRNA miR-153 and its host gene Ia-2 beta: identification of miR-153 target genes with functions related to IA-2beta in pancreas and brain. Diabetologia. 2013; 56: 1547-56.
42. Bao B, Rodriguez-Melendez R, Zempleni J. Cytosine methylation in miR-153 gene promoters increases the expression of holocarboxylase synthetase, thereby increasing the abundance of histone H4 biotinylation marks in HEK-293 human kidney cells. J Nutr Biochem. 2012; 23: 635-9.
43. Balaraman S, Winzer-Serhan UH, Miranda RC. Opposing Actions of Ethanol and Nicotine on MicroRNAs are Mediated by Nicotinic Acetylcholine Receptors in Fetal Cerebral Cortical-Derived Neural Progenitor Cells. Alcohol Clin Exp Res. 2012.
44. Agarwai MK. The antiglucocorticoid action of mifepristone. Pharmacology & therapeutics. 1996; 70: 183-213.
45. Lin MF, Kawachi MH, Stallcup MR, et al. Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. The Prostate. 1995; 26: 194-204.
46. Maria B. Hapon CDG-L, Alicia A. Goyeneche, Eduardo A. Callegari, Kathleen M. Eyster, and Carlos M. Telleria. Induction of the unfolded protein response in ovarian cancer cells exposed to cytostatic concentrations of antiprogestin/antiglucocorticoid mifepristone. [abstract]. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19: Abstract_nr_A23.
47. Chang CJ, Yang JY, Xia W, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer cell. 2011; 19: 86-100.
48. Dubrovska A, Kim S, Salamone RJ, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106: 268-73.
49. Guo W, Keckesova Z, Donaher JL, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 2012; 148: 1015-28.
50. Cordenonsi M, Zanconato F, Azzolin L, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147: 759-72.
51. Poole AJ, Li Y, Kim Y, et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006; 314: 1467-70.
52. Skor MN, Wonder EL, Kocherginsky M, et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19: 6163-72.
53. Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception. 2003; 68: 409-20.
54. Garbe JC, Bhattacharya S, Merchant B, et al. Molecular distinctions between stasis and telomere attrition senescence barriers shown by long-term culture of normal human mammary epithelial cells. Cancer research. 2009; 69: 7557-68.
55. Perrault D, Eisenhauer EA, Pritchard KI, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1996; 14: 2709-12.